PRCM
PVLA

Pine River Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Pine River Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,375
Closed -$963K – 747
2015
Q2 		$963K Buy
+4,375
New +$963K 0.01% 469

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Pine River Capital Management's PVLA Position: Q3 2015 in Review

Pine River Capital Management sold out of Palvella Therapeutics (PVLA) in Q3 2015, closing a stake of 4,375 shares — an estimated $963K sold.

Pine River Capital Management first reported a position in PVLA in Q2 2015 and held it in 1 quarter. The position peaked at $963K in Q2 2015. 13 funds tracked by Wall St. Rank hold PVLA as of Q3 2015.

  • Pine River Capital Management reported no remaining Palvella Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Pine River Capital Management sold 4,375 Palvella Therapeutics shares in Q3 2015, an estimated $963K.
  • Pine River Capital Management first reported a position in Palvella Therapeutics in Q2 2015 and held it in 1 quarter.
  • Pine River Capital Management's Palvella Therapeutics position peaked at $963K in Q2 2015.
  • 13 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2015.

Based on Pine River Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.